Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Controlled Mechanism Study of Thymosin Alpha-1 in Reshaping the "Immune Resilience" Trajectory of Immunosuppressed Sepsis Patients

NCT07866118 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT07866118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07866118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Controlled Mechanism Study of Thymosin Alpha-1 in Reshaping the "Immune Resilience" Trajectory of Immunosuppressed Sepsis Patients
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
October 6, 2026
Completion date
September 1, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunosuppression, sepsis